Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Arch. endocrinol. metab. (Online) ; 59(6): 515-522, Dec. 2015. tab
Article in English | LILACS | ID: lil-767927

ABSTRACT

Objective To report our experience of treating central precocious puberty (CPP) with a GnRH analogue with respect to the final heights (FH) attained in patients who completed treatment. Subjects and methods Among 105 records of children diagnosed with precocious puberty, 62 cases (54 girls and 8 boys), who were treated with leuprolide acetate/3.75 mg/monthly, were selected, and divided into 4 groups: group 1 (G1), 25 girls who attained FH; group 2 (G2), 18 girls who completed treatment but did not reach FH; group 3 (G3), 11 girls still under treatment; and group 4 (G4), 8 boys, 5 of which attained FH. Treatment was concluded at a bone age of 12 years, and follow-up continued until FH was achieved. Results In both G1 and G2 groups, height standard deviation score (SDS), weight-SDS and percentile of body mass index (PBMI) did not show intra/intergroup differences at the beginning and at interruption of treatment, but when added, G1+G2, height-SDS and weight-SDS differed significantly (p = 0.002 and 0.0001, respectively). In G1, 19 of 25 cases attained TH, and average height gain was 16.7 cm (7.7- 27.1); there was significant difference between FH and prediction of FH at the start (PFH at start) (p = 0.0001), as well as between PFH at interruption vs TH and vs FH (p = 0.007) with FH higher than TH (p = 0.004). Significant correlation was identified between FH and height gain after treatment. Conclusion As shown by some studies, GnRH analogue treatment was effective in children with CPP reaching FH near the genetic target.


Subject(s)
Child , Child, Preschool , Female , Humans , Infant , Male , Body Height/drug effects , Fertility Agents, Female/therapeutic use , Gonadotropin-Releasing Hormone/analogs & derivatives , Leuprolide/therapeutic use , Puberty, Precocious/drug therapy , Age Determination by Skeleton , Brazil , Estradiol/blood , Follow-Up Studies , Follicle Stimulating Hormone, Human/blood , Luteinizing Hormone/blood , Puberty, Precocious/blood , Retrospective Studies , Treatment Outcome , Testosterone/blood
2.
Arq. bras. endocrinol. metab ; 54(7): 620-629, Oct. 2010. tab
Article in Portuguese | LILACS | ID: lil-564067

ABSTRACT

OBJETIVOS: Avaliar implicações do diabetes melito (DM) na morbimortalidade materno-fetal, segundo experiência da Universidade Federal do Triângulo Mineiro. MATERIAIS E METODOS: Procedeu-se à análise retrospectiva dos prontuários de gestantes diabéticas assistidas entre 1990 e 2009 focando dados e complicações maternas e neonatais. RESULTADOS: A última gestação de 93 diabéticas foi avaliada, sendo 34 com DM tipo 1, em que se observou maior ocorrência de tocotrauma (p = 0,023) e retinopatia (p = 0,023). Vinte e uma pacientes tinham DM tipo 2; suas necessidades de insulina aumentaram progressivamente (p < 0,01) e observou-se maior prevalência de tabagismo (p = 0,004). Trinta e oito tiveram diabetes gestacional e iniciaram acompanhamento do diabetes em idade gestacional mais tardia (p < 0,001), tiveram mais antecedentes de macrossomia fetal (p = 0,028) e maior prevalência de fatores de risco cardiovascular. CONCLUSÕES: Não obstante melhora do controle glicêmico durante a gestação, nenhum dos grupos atingiu alvos glicêmicos ideais. Ainda assim, a maioria das gestações em diabéticas, conduzidas em nosso meio, evoluiu favoravelmente.


OBJECTIVES: Evaluation of the consequences of diabetes mellitus (DM) on maternal and fetal morbidity and mortality at Universidade Federal do Triângulo Mineiro. MATERIALS AND METHODS: A retrospective review of medical records of pregnant women with diabetes was carried out at the hospital between 1990-2009, focusing on maternal and neonatal data and complications. RESULTS: The last pregnancy of 93 diabetics was evaluated. In thirty-four patients with type 1 diabetes a higher incidence of birth trauma (p = 0.023) and retinopathy (p = 0.023) was observed. Twenty-one type 2 DM subjects required progressively increased insulin therapy (p < 0.01) and showed a higher prevalence of smoking (p = 0.004). Thirty-eight had gestational diabetes. Their diabetic follow-up started at a later gestational age (p < 0.001), had more fetal macrosomia histories (p = 0.028) and cardiovascular risk factors. CONCLUSIONS: Despite improvement of glycemic control during pregnancy neither group attained the glycemic target. However, the majority of DM pregnancies evaluated in our group presented successful outcomes.


Subject(s)
Adult , Female , Humans , Pregnancy , Diabetes Complications/prevention & control , Diabetes Mellitus, Type 1/mortality , /mortality , Maternal Health Services/standards , Pregnancy Outcome/epidemiology , Pregnancy in Diabetics/mortality , Brazil/epidemiology , Diabetes Complications/mortality , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/therapy , /complications , /therapy , Epidemiologic Methods , Fetal Death/epidemiology , Hospitals, University , Monitoring, Physiologic/standards , Mothers/statistics & numerical data , Perinatal Mortality , Pregnancy in Diabetics/therapy
SELECTION OF CITATIONS
SEARCH DETAIL